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Abstract: The aim of this study is to identify gene expression profiles associated with hyaluronic
acid (HA) treatment of normal and osteoarthritis (OA)-like tissue-engineered cartilage. 3D cartilage
micromasses were treated with tumour necrosis factor-α (TNF-α) (OA-inducer) and/or HA for 7 days.
Viability was examined by PI/FDA staining. To document extracellular matrix (ECM) formation,
glycosaminoglycans (GAG) were stained with Safranin-O and cartilage-specific type II collagen was
detected immunohistochemically. Genome-wide gene expression was determined using microarray
analysis. Normal and OA-like micromasses remained vital and showed a spherical morphology
and homogenous cell distribution regardless of the treatment. There was no distinct difference in
immunolabeling for type II collagen. Safranin-O staining demonstrated a typical depletion of GAG in
TNF-α-treated micromasses (−73%), although the extent was limited in the presence of HA (−39%).
The microarray data showed that HA can influence the cartilage metabolism via upregulation of
TIMP3 in OA-like condition. The upregulation of VEGFA and ANKRD37 genes implies a supportive
role of HA in cartilage maturation and survival. The results of this study validate the feasibility of the
in vitro OA model for the investigation of HA. On the cellular level, no inhibiting or activating effect
of HA was shown. Microarray data demonstrated a minor impact of HA on gene expression level.
Keywords: hyaluronic acid; osteoarthritis; in vitro model; microarray
1. Introduction
Hyaluronic acid (HA) is a main component of articular cartilage, which provides the backbone
of large proteoglycan complexes. HA binds to a cluster of differentiation 44 (CD44) receptors and
this binding inhibits interleukin (IL)1β expression and leads to a decline in matrix metalloproteinase
(MMP) 1, 2, 3, 9 and 13 production [1]. Moreover, HA, lubricin and phospholipid species endow
synovial fluid with its viscoelastic properties and contribute independently or together to lubrication of
the articular surfaces [2,3]. As osteoarthritis (OA) progresses, natural concentration of HA and lubricin
as well as the molecular weight distribution of HA shift toward the lower ranges, which deteriorates
the mechanical/viscoelastic properties of the synovial fluid [3]. Intra-articular HA administration
has aimed to restore these properties [4], although there is controversy over its underlying attributes.
Apart from shock absorption and joint lubrication, some therapeutic mechanisms of HA in the OA
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joint are also proposed such as protective effects on cartilage, enhancement of proteoglycan synthesis
and reduction of inflammation [5]. The proposed mechanisms and their controversial discussion
encouraged us to investigate the manifold effects of HA on normal and OA-like tissue-engineered
cartilage on the cellular and molecular level. Our general aim is to create a better understanding of
how intra-articular HA treatment could provide therapeutic effects.
In order to address this question we used an established in vitro OA model which offers a
high-throughput analysis of potential active substances in a reproducible and very well characterized
approach under standardized conditions [6,7]. In 2014, Schlichting et al. [7] overcame the low
availability of human primary tissue and disadvantages of animal models by using cells from porcine
cartilage sources. They thus developed an easy to manage OA model by introducing tumour necrosis
factor-α (TNF-α) into a 3D-micromass culture, which has already been shown to mimic essential
aspects of human chondrocyte and native cartilage biology, pathophysiology and differentiation.
TNF-α addition established a degradative environment in line with the generation of macroscopic
changes such as extensive proteoglycan loss as an implicit feature of human OA. Furthermore, gene
expression profiling of porcine tissue-engineered cartilage micromasses revealed human OA reaction
pattern such as extensive ECM loss (collagen type 2 (COL2A1), collagen type 9 (COL9A1), cartilage
oligomeric compound (COMP), aggrecan (ACAN)), cell death, formation of an inflammatory environment
through the induction of genes coding for chemokines (interleukin 8 (IL8), C-C motif chemokine 2 (CCL2))
and OA-relevant enzymes (matrix metalloproteinase1, 13 (MMP1, 13)) and the modulation of genes
involved in skeletal development [7].
To study the effects of HA on cartilage formation and maintenance, 3D chondrocyte micromasses
were cultured for 14 days to form extracellular matrix (ECM) and were stimulated for further 7 days
with HA under normal and OA-like conditions (by adding TNF-α). Parameters such as cell survival,
ECM formation, or changes in gene expression profiles were investigated to evaluate the physiologic
action of HA on the cellular and molecular level.
2. Results
2.1. Effect of Hyaluronic Acid on Chondrocyte Viability and Extracellular Matrix Formation
To examine the HA effect on normal and OA-like tissue-engineered cartilage on cellular level we
obtained fluorescent images from the live/dead assay which demonstrated that all tissue-engineered
chondrocyte micromasses in this study remained vital. (green; Figure 1A–E). Furthermore, the images
showed a homogenous distribution of chondrocytes within the ECM and displayed a spherical
morphology of cells over a period of 21 days throughout the culture conditions (Figure 1A–E).
Immunohistochemical staining of cartilage-characteristic collagen type II revealed the secretion of this
protein as a component of the formed matrix in 3D cartilage micromasses after 14 days (starting point)
and after 7 days stimulation with TNF-α or treatment with HA regardless of the combination with
TNF-α (Figure 1F–J).
During culture, micromasses have developed an ECM rich in proteoglycans at day 14 (starting
point), histologically detected by Safranin-O staining (Figure 1K). Afterwards micromasses were treated
for further 7 days with TNF-α alone or with HA under normal and OA-like conditions, where the addition
of TNF-α expedited OA pattern-oriented changes including GAG depletion. The histological sections
from these samples showed less accumulation of GAGs in TNF-α-treated groups with marginal increase
in HyaTNF in comparison to TNF-α (Figure 1L–O). HA alone led to a non-significant increase of GAG.
The histomorphometric analysis further confirmed that GAG accumulation was significantly
reduced in TNF-α-treated groups compared to control groups and HA addition did not lead to any
significant alterations (Figure 2). The mean intensity at starting point was 114.10 ± 10.16; after further
7 days the mean intensity of control (Ctr) was 134.86 ± 9.25. No significant differences were detected
between the control group and the Hya group (Hya: 152.60 ± 18.70). TNF-α-stimulated samples had
a significant decrease of GAGs regardless of HA presence (TNF: 35.81 ± 9.94, HyaTNF: 82.09 ± 20.51),
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although HyaTNF showed less depletion than TNF (p-value = 0.071). In summary, all these data
demonstrated that the model we used worked properly as a highly useful approach for in vitro
cartilage and OA studies. More importantly, the data showed no inhibiting or activating effect of HA
on tissue-engineered normal or OA cartilage on cellular level.
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Figure 1. Chondrocyte Viability and Cartilage Quality. (A–E) Live-dead staining of micromasses of all
5 experimental groups. Living cells were stained green using FDA; dead cells were stained red using
PI. (F–J) Immunohistochemistry demonstrated the presence of cartilage-specific collagen type II (red)
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2.2. In Vitro Model Verification by Cartilage-Related Markers
In order to gain insight into the gene expression pattern of normal and OA-like micromasses that
have been treated with HA, a icroarray analysis with genome-wide Affymetrix GeneChip porcine
arrays was perfo med.
To verify the suitability of the 3D cartilage micromasses also on the molecular level, the 14-day
micromasses (starting point) were examined for cartilage-related marker genes that were selected
based on the data of our reference model paper (Table 1, d14_Ref) [7]. Our expression data showed the
same present-absent pattern in almost all (except for Serpin Family A Member 3, SERPINA3) selected
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cartilage markers (Table 1, d14_start point) consisting of collagen type 2, 9 (COL2A1, COL9A1), ECM
connectors (hyaluronan and proteoglycan link protein 1; HAPLN1, proline and arginine-rich end leucine-rich
repeat protein; PRELP) and other players of structural integrity of cartilage (cartilage intermediate layer
protein; CILP, cartilage oligomeric matrix protein; COMP), enzymes (matrix metallopeptidase 3; MMP3,
serpin family A member 1; SERPINA1), growth factors (fibroblast growth factor 2; FGF2, insulin-like growth
factor binding protein 3; IGFBP3), proteoglycans (aggrecan; ACAN, chondroitin sulphate proteoglycan 4;
CSPG4), receptors (fibroblast growth factor receptor 1, 3; FGFR1, 3) and transcription factors (SRY-box 6, 9;
SOX6, 9). Further cultivation up to day 21 (Ctr) did not lead to any changes in this regard (Table 1,
(d21) Ctr). In favour of demonstrating OA alterations after TNF-α stimulation, we compared the
TNF-α-stimulated micromasses (TNF) with non-stimulated micromasses (Ctr). Roughly 85% of the 41
selected cartilage marker genes were significantly up- or downregulated; the fold changes (FC) are
given in Table 1. These results are in line with our previously published data [7] and with the Safranin-O
staining results (Figure 1K–O). In summary, these extensive similarities and the cartilage marker gene
profiles given in Table 1 proved the reproducibility and suitability of the porcine micromass model for
testing on the molecular level.
Table 1. Overview of gene expression of selected cartilage markers.
Gene








COL1A2 collagen type I α2 + + + −2.7
COL2A1 collagen type II α1 + + + −25.8
COL9A2 collagen type IX α1 + + + −11.0
ECM
connectors
FMOD fibromodulin + + + −1.3
HAPLN1 hyaluronan and proteoglycan link protein 1 + + + −9.5
LGALS3 carbohydrate-binding protein 35 + + + 1.2
PCOLCE2 C-endopeptidase enhancer 2 + + + /
PRELP prolargin + + + −1.9
Enzymes
MMP3 matrix metallopeptidase 3 + + + 19.9
SERPINA1 serpin peptidase inhibitor clade A member 1 + + + −31.3
SERPINA3 serpin peptidase inhibitor clade A member 3 - + + /
Growth
factors
BMP2 bone morphogenetic protein 2 + + + /
BMP4 bone morphogenetic protein 4 + + + −1.8
BMP7 bone morphogenetic protein 7 - - - 3.2
FGF18 fibroblast growth factors 18 - - - −2.6
FGF2 fibroblast growth factors 2 + + + 4.6
FGF9 fibroblast growth factors 9 - - - −3.6
IGF1 insulin-like growth factor 1 + + + −2.8
IGFBP3 insulin-like growth factor binding protein 3 + + + 4.2
TGFB1 transforming growth factor beta 1 + + + −1.6
TGFB2 transforming growth factor beta 2 + + + 1.6
TGFB3 transforming growth factor beta 3 + + + −2.6
THRA thyroid hormone receptor α + + + −1.7
Proteoglycan
ACAN aggrecan + + + −13.1
BGN biglycan + + + −2.6
CSPG4 chondroitin sulphate proteoglycan 4 + + + −3.8
DCN decorin + + + −2.4
HSPG2 heparan sulphate proteoglycan 2 + + + /
VCAN versican + + + /
Receptors
FGFR1 fibroblast growth factor receptor 1 + + + −1.2
FGFR2 fibroblast growth factor receptor 2 + + + −1.7




CHI3L1 cartilage intermediate layer protein + + + 1.8
CILP cartilage oligomeric protein + + + 7.9
COMP extracellular matrix protein 1 + + + −8.6
ECM1 fibrillin 1 + + + 4.0
FBN1 fibronectin 1 + + + 2.4
FN1 matrix gla protein + + + /
MGP cartilage intermediate layer protein + + + −2.1
Transcription
factors
SOX6 SRY (Sex Determining Region Y)-Box 6 + + + −3.3
SOX9 SRY (Sex Determining Region Y)-Box 9 + + + /
+ (Bold) = present in all 3 replicates, + = present in some replicates, - = absent in all replicates, / = no significant fold
change, FC = fold change. * = [7].
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2.3. Gene Expression Profiling as Response to HA Treatment
In order to get a deeper insight into the HA effects, 14-day old micromasses that were further
treated for 7 days with HA were compared with non-HA-treated normal and OA-like micromasses.
Hierarchical clustering analysis based on all the probes of day 21 including the HA-treated groups
was performed to explore the variability and similarity of gene expression at day 21 (12 samples),
which therefore showed possible HA effects. Considering the expression pattern of tissue-engineered
cartilage, hierarchical clustering resulted in two main groups, classified as TNF-α-treated and
non-TNF-α-treated (Figure 3A). The clustering showed no distinct clustering for HA-treated samples,
whereas HA-treated (without TNF-α) and normal chondrocytes (Ctr) clustered together. This similarity
indicated that HA did not cause any pronounced alterations in the gene expression pattern. Therefore,
no separate cluster was observed for the HA samples.
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2.4. Overview of Differentially Expressed Genes between Controls and Treated Groups
A Venn diagram was drawn to display the overlapping or unique members of the significantly
differentially expressed genes (DEGs) between treated groups and day 21 controls. As shown in
Figure 3, 16 DEGs were upregulated only in the Hya group (Figure 3B) and 6 were downregulated only
in the Hya group (Figure 3C). In HyaTNF, 233 upr gulated (Figure 3B) a d 241 downregulated DEGs
(Figure 3B) did not overlap with the other categories. The in ergroup test detected only 17 up egulated
(Figure 3B) and 4 downregulated DEGs (Figure 3C). A comparison between upregulated DEGs in
the HyaTNF and TNF groups revealed 1024 common genes (Figure 3B) and between downregulated
differentially expressed genes 1107 common genes. These results indicated similarities in the gene
expression pattern of only HA-treated samples and controls, whereas TNF-α triggered different gene
expressi n patterns regardless of HA prese t.
We further analysed the 47 DEGs detected betwe n Hya and Ctr groups, including 36 upregulated
and 11 downregulated genes (Figure 3A,B and Table S1). According to the heat map, the HA samples
and normal micromasses (Ctr) could be well distinguished using these screened significantly regulated
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genes (Figure 4). The most upregulated genes (FC > 2.50) are ankyrin repeat domain 37 (ANKRD37;
FC = 3.00), vascular endothelial growth factor A (VEGFA; FC = 3.00), serpin family E member 1 (SERPINE1;
FC = 2.90), solute carrier family 2, member 3 (SLC2A3; FC = 2.80) and the most downregulated genes
include MMP3 (FC = −2.00), guanylate binding protein 1 (GBP1; FC = −1.80), epiphycan (EPYC;
FC = −1.70) and angiotensinogen (AGT; FC= −1.70). 3 genes namely of C-C motif chemokine 2 (CCL2;
FC = 2.08), vascular endothelial growth factor (VEGF; FC = 2.99) and matrix metalloproteinase 3
(MMP3; FC =−1.95) out of these 47 DEGs are involved in an arthritis pathway showing minor changes
in the presence of HA in this context.
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To detect the HA effect on OA-like cartilage we performed a comparative microarray analysis,
which identified a total number of 101 genes that were differentially regulated between HyaTNF
and TNF (Table 2). The screened DEGs were totally enriched in 35 GO terms, including 5 cellular
component (CC) terms, 6 molecular function (MF) terms and 24 biological process (BP) terms according
to the functional annotation. The top 20 terms are shown in Table 2, which were mainly related to
CC terms such as extracellular space and basement membrane and genes enriched in these terms
included angiopoietin-like 4 (ANGPTL4), apelin (APLN), C-X-C motif chemokine ligand 3 (CXCL3), IGFBP3,
5, 6, COL4A1, COL14A1, extracellular matrix protein 1 (ECM1), prostaglandin D2 synthase (PTGDS), tissue
inhibitor of metalloproteinase 3 (TIMP3), secreted frizzled related protein 1 (SFRP1) and VEGFA.
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Table 2. The top 20 GO terms from enrichment analysis of DEGs (HyaTNF vs. TNF) sorted according to p-value.
Category GO ID GO Name Gene Nr. p-Value Genes
CC GO:0005615 extracellular space 16 3.0 × 10−4
CXCL3, IGFBP6, LMCD1, PLBD1, ECM1, TIMP3, COL14A1,
PTGDS, SFRP1, HIST2H2BE, GPX3, VEGFA, IGFBP3, APLN,
ANGPTL4, IGFBP5
MF GO:0001968 fibronectin binding 3 2.3 × 10−4 VEGFA, IGFBP3, IGFBP5
MF GO:0031994 insulin-like growth factor I binding 3 3.4 × 10−4 IGFBP6, IGFBP3, IGFBP5
MF GO:0031995 insulin-like growth factor II binding 3 3.4 × 10−4 IGFBP6, IGFBP3, IGFBP5
BP GO:0043567 regulation of insulin-like growthfactor receptor signalling pathway 3 6.9 × 10
−4 IGFBP6, IGFBP3, IGFBP5
CC GO:0005604 basement membrane 4 1.8 × 10−3 P3H2, COL4A1, ITGA6, TIMP3
BP GO:0071456 cellular response to hypoxia 4 2.1 × 10−3 PTGS2, SFRP1, VEGFA, ANGPTL4
BP GO:0045663 positive regulation of myoblastdifferentiation 3 3.7 × 10
−3 CDON, BOC, IGFBP3
BP GO:0045892 negative regulation of transcription,DNA-templated 6 9.5 × 10
−3 CRY2, SFRP1, BEND5, CCDC85B, BASP1, HMGA1
CC GO:0005576 extracellular region 8 9.7 × 10−3 FGF7, PTGDS, PAPPA, AGT, NMB, FGF13, CFD, GHR
BP GO:0001558 regulation of cell growth 3 1.4 × 10−2 IGFBP6, IGFBP3, IGFBP5
BP GO:0017148 negative regulation of translation 3 1.7 × 10−2 BTG2, ENC1, IGFBP5
CC GO:0042567 insulin-like growth factorternary complex 2 1.9 × 10
−2 IGFBP3, IGFBP5
CC GO:0070062 extracellular exosome 18 2.2 × 10−2
SCPEP1, IGFBP6, NPR3, ECM1, TIMP3, ARG1, COL14A1, BTG2,
SFRP1, PTGDS, RAB19, HIST2H2BE, AGT, PCBP2, BLVRB,
GPX3, IGFBP3, MEST
BP GO:0044342 type B pancreatic cell proliferation 2 3.5 × 10-2 IGFBP3, IGFBP5
BP GO:0014912 negative regulation of smooth musclecell migration 2 3.5 × 10
−2 IGFBP3, IGFBP5
BP GO:0006979 response to oxidative stress 3 3.8 × 10−2 PTGS2, GPX3, SRXN1
BP GO:0043568
positive regulation of insulin-like
growth factor receptor
signalling pathway
2 4.0 × 10−2 IGFBP3, IGFBP5
BP GO:0045893 positive regulation of transcription,DNA-templated 5 4.0 × 10
−2 FGF7, SFRP1, AGT, SERTAD3, HMGA1
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3. Discussion
The present conflicting data regarding the controversial properties of HA, the standard
viscosupplement for OA [8], encouraged us to investigate more thoroughly its physiologic effect
on cellular and molecular level. Sun et al. have already proved that HA provide pain relief and
functional improvement in patients with ankle OA [9]. In another hypothesis-driven study it was
shown that HA exhibits a pronounced suppressive effect on MMP13 [10]. Although HA effects have
been studied before in patients to some extent and even during in vitro cartilage formation [11] this
study has been the first, to perform a global gene expression analysis on HA-treated normal and
OA-like tissue-engineered cartilage. Our findings showed no inhibiting or activating effect of HA
on tissue-engineered normal or OA-like cartilage on the cellular level. On the molecular lever, we
could observe minor changes in arthritis context but no pronounced alterations were caused by HA.
We could also confirm that the OA model we used was a highly useful approach for in vitro cartilage
and OA studies.
Since the OA chondrocytes can only maintain the pathologic condition for a short time under cell
culture conditions, long-term evaluations require the addition of OA-inducing agents. TNF-α and
IL1 are the most widely used cytokines to induce OA as well as rheumatoid arthritis. To induce OA
changes the inflammatory mediator TNF-α was used in this study. TNF-α is increased in the synovial
fluid of OA patients and is known to mediate the catabolic process [12]. The TNF-α concentration in
the synovial fluid of OA patients is in the lower range (e.g., 0.124 ± 1.59 pg/mL) [13] but in vitro the
concentration should be much higher (10 ng/mL) to achieve alterations in a shorter time.
Live-dead staining of 14-day micromasses, which were further treated for 7 days with 0.3 wt %
HA in normal and OA-like conditions (where TNF-α was added to simulate important aspects of OA),
revealed a majority of viable cells embedded in ECM. A normal morphology and even distribution of
cells through the matrix was observed in all experimental groups. On gene expression level, TNF-α
addition led to an induction of genes related to cell death such as TNFSF10, PMAIP1, AHR and
ADM that was not altered by the addition of HA. Consequently, HA did not prevent the induction
of pathways related to cell death such as apoptosis and autophagy but HA did not cause any cell
death stimulation under normal and OA-like conditions compared to control group and starting
point. We used 0.3 wt % concentration of HA to mimic the in vivo situation, because in healthy
human synovial fluid, a broad range of HA concentrations was measured ranging between 0.05 and
0.4 wt %, with 0.3 wt % being typical [14]. Collagen type II immunostaining did not reveal any specific
differences between experimental groups, which is in line with the previous published data [7]. It has
been shown that the total collagen loss was not pronounced in this model and HA did not seem to
change this pattern either. Smyth et al. have recently shown in a rabbit model that addition of HA
caused no noticeable difference in the type-II collagen immunoreaction between the HA-treated grafts
and the controls [15]. Proteoglycan depletion plays a main role in the histopathological assessment of
OA grade [16] and is a detectable feature in this model. Addition of TNF-α, a well-known mediator of
acute inflammation in cartilage pathology, triggered a clear depletion of GAG in HA-treated as well as
non-treated micromasses. However, there was less decrease of GAG observed in HyaTNF. This can be
explained by the study of Greenberg et al. who concluded from their cartilage synovium co-culture
model that HA inhibits the MMP- and IL1-mediated decrease in glycosaminoglycan production by
cartilage explants [17] and this chondrostimulative effect was further confirmed by Elmorsy et al.
in vivo [4]. These observations in connection with gene expression alterations caused by addition of
TNF-α (Table 1) showed the feasibility of the porcine micromass model to assess HA influence on
normal and OA cartilage.
Comparative genome-wide expression analysis of porcine micromasses treated with HA and the
non-treated micromasses revealed a total of 47 dysregulated genes (Figure 3) including up-regulation
of ANKRD37, VEGFA, SERPINE1, SLC2A3 as well as gene coding for chemokine CCL2 and
downregulation of MMP3, GBP1, EPYC and AGT. ANKRD37 is associated with hypoxia and cell
respond to hypoxic environment is upregulation of ANKRD37 RNA. Here the HA provoked the same
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response. It has been shown that this could lead to increased cartilage-specific gene expression, for
example, ACAN and Sox9 [18]. This could be the reason why we observed an insignificant increase
in GAG content of HyaTNF. VEGFA has a role in cartilage maturation and is critical for chondrocyte
survival [19]. Its upregulation in this study together with ANKRD37 upregulation confirms the existing
findings that HA can reduce chondrocyte apoptosis and enhance ECM synthesis [20]. SERPINE1 has a
function in complement cascade and its upregulation has been reported in OA-affected cartilage [21].
SLC2A3 encodes GLUT3, a glucose transporter and plays an essential role in chondrocyte metabolism
and physiology and can also be upregulated as a result of hypoxia. This hypoxia-like influence of
HA can be explained due to its high viscosity that restrains the diffusion of oxygen. Previous studies
have demonstrated that HA has the potential to inhibit the activity of matrix metalloproteinases
and catabolic cytokines [22]. In the present study, we did not detect any significant changes in
MMPs by the addition of HA in the OA-like condition. Interestingly, the TIMP3 was upregulated
in HA-treated OA-like micromasses. The chondroprotective role of TIMP3 is illustrated by studies
showing that mice lacking the gene for TIMP3 develop accelerated OA as they age [23] and, conversely,
that recombinant TIMP3 inhibits development of OA in a rat model of disease [24]. Although no
HA-dependent alterations in collagen type II deposition were detected, the finding is in line with
previous studies. GBP1 is an enzyme-binding protein, which showed an increase under rheumatoid
arthritic conditions [25] and HA-treated micromasses showed the reverse trend. We have also observed
the downregulation of EPYC, which is a marker enriched in growth plate cartilage and is used to
identify hyaline cartilage subtype [26].
We have further compared gene expression of HyaTNF group to TNF in order to study the
genes that are dysregulated by HA treatment under OA conditions. We found an increased level of
IGF-binding proteins (IGFBP) in HyaTNF. Insulin-like growth factor 1 (IGF1) is the most likely candidate
to affect the anabolism (synthesis of both collagen type II and proteoglycan core protein) of cartilage
matrix molecules and IGFBPs have a high affinity for IGF1 [27]. From our data (Table 2) we can
conclude that HA can possibly influence the cartilage anabolism via binding to IGFs and stabilize the
chondrocyte phenotype in pathological conditions. CXCL3 chemokine has been reported to have an
increased expression in OA cartilage [28]. HA seems to hamper this event by 2-fold downregulation.
GPX3 is involved in oxidative damage defence and is downregulated in OA cartilage [29]. In our study
HA appears to amplify this trend (FC = −2.6) in OA-like cartilage but not in healthy micromasses,
which shows that the effect is caused by TNF-α addition and not by HA.
HA with different molecular weight and consistencies are known to have different clinical
outcomes. In our study, we used one type of HA, namely OSTENIL®. Therefore, further investigation
of more HAs with different molecular weights and concentrations is necessary.
Based on our previous study, a sulphated polyethylene glycol hydrogel with anti-inflammatory
properties has viscoelastic properties that are comparable to HA for intra-articular injection, where
for medical applications the above-mentioned hydrogel has the advantage of being much less easily
displaced from its injection place than HA [30]. Comparing HA with such alternative candidates that
have disease-modifying properties is required for the development of better therapeutics.
This study has several limitations, including lack of verification for the findings on protein level,
which can lead to an increased evidence level of the study. Furthermore, the pathophysiological
changes in OA do not only influence articular cartilage but also other parts of the synovial joint such
as subchondral bone and joint capsule. Therefore, the effect of HA needs to be further investigated
thoroughly on these tissues as well. Another limitation is that the HA concentration used in this study
is thinner than the actual clinical concentration to enable the pipetting and the exchange of metabolites.
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4. Materials and Methods
4.1. Chondrocyte Isolation
Chondrocytes were isolated from the medial and lateral femoral condyle cartilage of 9 domestic
pigs according to a previously published protocol [31]. No animal approval was needed because the
samples were obtained from a local slaughterhouse. Briefly, cartilage pieces were incubated for 19 h in
spinner flasks containing Roswell Park Memorial Institute (RPMI) medium, supplemented with 10%
foetal bovine serum (FBS, Thermo Fisher Scientific, Dreieich, Germany), 100 U/mL penicillin (Pen)
and 100 µg/mL streptomycin (Strep), 333.3 U/mL collagenase II (all Merck, Darmstadt, Germany),
1 U/mL collagenase P (Roche Diagnostics, Mannheim, Germany) and 33.3 U/mL hyaluronidase
(Sigma-Aldrich, Steinheim, Germany). Afterwards, cell suspensions were filtered through a 100 µm
nylon mesh (Becton Dickinson, Heidelberg, Germany), washed in Hanks solution (Merck) and
resuspended in culture medium consisting of RPMI, 10% FBS, 100 U/mL Pen, 100 µg/mL Strep
and 170 µM L-ascorbic acid (Sigma-Aldrich).
4.2. Preparation of 3D-Chondrocyte Micromass Cultures
After chondrocyte isolation from 9 donors, cells of three different donors were pooled together in
one sample pool, resulting in three different sample pools. A volume of 200 µL containing 6 × 105
freshly isolated chondrocytes in culture medium was transferred to each well of 96-well flat bottom
plates (Becton Dickinson) to generate a high-density micromass culture (tissue-engineered cartilage) [7].
Subsequently, the culture plates were incubated for 24 h (37 ◦C, 5% CO2) to ensure cell sedimentation.
The medium was changed daily. Micromasses were allowed to form ECM for 14 days and then were
treated for further 7 days with HA alone (MW=1.2 KDa; OSTENIL®, TRB Chemedica, Germany),
TNF-α alone (R&D Systems, Wiesbaden, Germany) to induce OA-like changes, or in combination
thereof. This resulted in 5 experimental groups: (1) micromasses cultured for 14 days (start point)
and (2) further cultured for 7 days without treatment (control; Ctr) or treatment (3) with 0.3 wt % HA
diluted in culture medium (Hya), (4) 0.6 nmol/l TNF-α diluted in culture medium, or (5) a combination
of (3) and (4) (HyaTNF).
4.3. Live/Dead Assay
To demonstrate the cell viability of the micromasses, propidium iodide/fluorescein diacetate
(PI/FDA) staining (Sigma-Aldrich) was performed. The micromasses were washed with PBS and
stained with FDA under darkness. To prepare the FDA staining solution 1 mg/mL FDA were dissolved
in acetone and further diluted to a concentration of 3 µg/mL in PBS. Then, the samples were rinsed
with PBS before being counterstained with PI. To prepare the PI staining, 1 mg/mL PI were dissolved
in distilled water and further diluted to a concentration of 0.1 mg/mL in PBS. After an additional
washing step, the micromasses were analysed under a fluorescent microscope (Olympus CKX41,
Hamburg, Germany).
4.4. Histological and Immunohistochemical Staining
To document ECM formation or loss, micromasses that were embedded in an optimal cutting
temperature compound (Sakura Finetek, Staufen im Breisgau, Germany) were cryosectioned at 8 µm
and mounted on glass slides. Sulphated cartilage glycosaminoglycans (GAGs) were stained with 0.7%
Safranin-O in 67% ethanolic solution and cell nuclei were counterstained with 0.2% Fast Green in 0.3%
acetic acid. Stainings were photodocumented using a light microscope (AX 10, Zeiss, Jena, Germany).
The intensity of the Safranin-O staining is directly proportional to the GAG amount of the tissue and
can therefore be called a semi-quantitative histochemical method [32]. Therefore a histomorphometric
analysis was performed as previously described [7]. Briefly, pictures were taken and all pixels in the
areas of interest were valued in the RGB colour mode with a tool based on Xcode (Apple, Sunnyvale,
CA, USA). When the red value (R) multiplied by 2 was higher than the sum of the green (G) and
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blue (B) values, the pixel was counted as red. The intensity of each red pixel was calculated with this
formula: intensity = 2 × R-value − G-value − B-value. Values of the intensity ranged between 1 and
510. The mean intensity (sum of intensities/area of interest) was calculated from each image.
Collagen type II expression was analysed by immunohistochemistry with polyclonal mouse
anti-porcine type II collagen antibodies (Calbiochem CP18, Merck, Darmstadt, Germany). Mouse IgG
(DAKO, Hamburg, Germany) served as a control. EnVision detection antibody was used to visualize
collagen type II antibodies and nuclei were counterstained with hematoxylin (DAKO).
4.5. RNA Isolation
Total RNA was isolated from micromasses that were cultured over 21 days. For each individual
replicate (n = 3) of each experimental group, 5 micromasses were snap-frozen in liquid nitrogen
and stored at −80 ◦C until further use. The frozen samples were transferred to 1 mL TriReagent
(Sigma-Aldrich) and mechanically homogenized. Subsequently, 133 µL 1-bromo-3-chloro-propane
(Sigma-Aldrich) was admixed followed by centrifugation for 45 min at 13,000× g. The aqueous phase
was collected and supplemented with same volume of 70% ethanol. Further purification was performed
according to protocol for animal tissues of the RNeasy Mini Kit (Qiagen, Hilden, Germany). The RNA
concentration was determined by the Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific).
The integrity of the RNA was determined by the Agilent Bioanalyzer 2100 (Agilent Technologies, Santa
Clara, CA, USA). The RNA samples used in this study had an integrity number above 8.9.
4.6. Microarray Analysis
Altogether, data from 15 microarray experiments (5 groups in triplicates) are included in this
study, from which selected data of 6 microarrays (triplicates of Ctr and TNF groups) have already been
published in a study with a totally different focus on sulphated polyethyleneglycol hydrogels as a
possible HA alternative [33].
A total of 23,937 probe sets representing 20,201 porcine genes were covered in the Affymetrix
GeneChip porcine array (Affymetrix, Freiburg, Germany). RNA processing and hybridization were
performed according to the manufacturer’s protocol. The GeneChips were scanned with the Affymetrix
GeneChip scanner 3000. Raw gene expression data were normalized and analysed with GeneChip
operating software 1.4 (GCOS, Affymetrix). Comparisons between triplicates of the starting point
group and the Ctr group were performed on the basis of a cartilage-marker list associated with our
in vitro OA model [7]. Other paired group comparisons were performed between replicates of each
group (9 comparisons). Genes were selected for further analysis that showed (1) a significant signal
change, which was detected by GCOS for at least 7 out of 9 comparisons, (2) a 1.5 mean-fold change
and (3) a p-value < 0.05 applying t-test. To group genes with coherent expression profiles into modules,
we used complete linkage hierarchical clustering (HCL) with normalized log 2-transformed signals.
A Pearson correlation was done to determine the distance measure and complete linkage clustering by
agglomeration rule, using Genesis 1.7.6 software [34]. Gene ontology (GO) terms analysis, biological
process (BP) function enrichment analysis and Kyoto encyclopaedia of genes and genomes (KEGG)
pathway enrichment analysis of differentially expressed genes was performed using the database
for annotation, visualization and integrated discovery (DAVID) [35]. In order to find the names for
unnamed porcine probe set IDs, we used cross-species relationships between porcine and human
probe set IDs (U133PlusVsPorcine_Complex sheet) in combination with human NetAffx annotation
file (HG_U133_Plus_2 Array, Affymetrix).
4.7. Statistical Analysis
The intensity of the Safranin-O stained areas are shown as the mean intensity normalized to the
control and standard deviation. A p-value lower than 0.05 was accepted as statistically significant.
The significance level of log 2-tranformed microarray data was determined with the independent
two sample t-test statistics of the Excel 2011 software package (Microsoft, Redmond, WA, USA).
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The normality of distribution was investigated applying the Anderson-Darling test [36] and the equal
variance of the compared sample groups was tested applying the f test [37,38]. The data showed
normal distribution with equal variance, therefore t-test was applied. Differences were considered
significant at p < 0.05.
The raw data is available for presentation to the referees and the editors of the journal, if requested.
The microarray data will be deposited in the GEO database.
5. Conclusions
In conclusion, the present study can further confirm that HA has a minor physiological impact
on normal and OA-like tissue-engineered cartilage compared to alterations caused by TNF-α.
Nevertheless, it can possibly influence the cartilage anabolism via stabilizing the chondrocyte
phenotype in pathological conditions. Moreover, the upregulation of VEGFA and ANKRD37 genes
confirms the chondrostimulative potential of HA and slow down degradation. Understanding these
HA-related modifications may serve as a guide toward imminent therapies. In addition to providing a
more comprehensive picture of HA influence, the results in this study further validate the feasibility of
in vitro OA model for the investigation of HA.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/
5/1519/s1. Table S1: Signal values of 47 differentially expressed genes and SLR (signal log ratios) between Ctr
and Hya.
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ANGPTL4 included angiopoietin-like 4




CCL2 C-C motif chemokine 2
CD44 cluster of differentiation 44
CILP cartilage intermediate layer protein
COL2A1 collagen type 2 alpha 1 chain
COL9A1 collagen type IX alpha 1 chain
COMP cartilage oligomeric compound
CSPG4 chondroitin sulphate proteoglycan 4
CXCL3 C-X-C motif chemokine ligand 3
DAVID database for annotation, visualization and integrated discovery
ECM extra cellular matrix
EPYC epiphycan
FBS foetal bovine serum
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FC fold change
FGF fibroblast growth factor
FGFR fibroblast growth factor receptor
GAG glycosaminoglycan
GBP1 guanylate binding protein 1
GCOS GeneChip operating software
GO gene ontology
HA hyaluronic acid
HAPLN1 hyaluronan and proteoglycan link protein 1
HCL hierarchical clustering
IGFBP insulin-like growth factor binding protein
IL interleukin





PI/FDA propidium iodide/fluorescein diacetate
PRELP proline and arginine-rich end leucine-rich repeat protein
PTGDS prostaglandin D2 synthase
SERPINA serpin family A member
SFRP1 secreted frizzled related protein 1
SLC2A3 solute carrier family 2 member 3
SOX SRY-Box
Strep streptomycin
TIMP3 TIMP metallopeptidase inhibitor 3
TNF-α tumour-necrosis factor-alpha
VEGFA vascular endothelial growth factor A
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